Article Text

Download PDFPDF

Cish actively silences tcr signaling in CD8+ T cells to maintain tumor tolerance
  1. Douglas Palmer1,
  2. Geoff Guittard2,
  3. Zulmarie Franco2,
  4. Shashank Patel2,
  5. Christopher A Klebanoff3,
  6. Madhusudhanan Sukumar3,
  7. Robert L Eil1,
  8. David Clever3,
  9. Lakshmi Balagopalan2,
  10. Rahul Roychoudhuri3,
  11. Larry Samelson2 and
  12. Nicholas Restifo2
  1. Aff1 grid.48336.3a0000000419368075NIH/NCI - Surgery Branch Bethesda MD USA
  2. Aff2 grid.48336.3a0000000419368075NCI Bethesda MD USA
  3. Aff3 grid.417768.b0000000404839129Center for Cancer Research, NCI/NIH Bethesda MD USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


Improving the functional avidity of effector T cells is critical in overcoming inhibitory factors within the tumor microenvironment and eliciting tumor regression.


We have found that Cish, a member of the Suppressor of Cytokine Signaling (SOCS) family, is induced by TCR stimulation in CD8+ T cells and inhibits their functional avidity against tumor.


Genetic deletion of Cish in CD8+ T cells enhances their expansion, functional avidity and cytokine polyfunctionality, resulting in pronounced and durable regression of established tumors. Although Cish is commonly thought to block STAT5 activation, we found that the primary molecular basis of Cish suppression is through inhibition of TCR signaling. Cish physically interacts with the TCR intermediate PLCg1, targeting it for proteasomal degradation following TCR stimulation. Furthermore we extend these findings to patients PBL retrovirally transduced with tumor-specific TCRs and shorthairpin microRNAs targeting CISH.


These findings establish a novel targetable interaction that regulates the functional avidity of tumor-specific CD8+ T cells and can be manipulated to improve adoptive cancer immunotherapy.